HOME >> BIOLOGY >> NEWS
Study could help transplant surgeons predict rejection/tailor medications

PITTSBURGH Oct. 11, 2006 A Children's Hospital of Pittsburgh of UPMC transplant surgeon and researcher has received a grant from the National Institutes of Health to study genetic factors that could predispose transplant recipients to rejection.

The goal of the four-year, $1.1 million grant is to study these factors in order to predict before transplant which patients are more likely to experience rejection. This information may be used to tailor anti-rejection medications accordingly, according to Rakesh Sindhi, MD, co-director of Children's Hillman Center for Pediatric Transplantation and principal investigator of the study. He plans to enroll 80 children receiving liver transplants at Children's.

"Based on the results of this study, a patient more likely to reject a transplanted organ may someday receive high doses of anti-rejection medicine initially. Those who are less likely to reject could have lower doses, or less potent combinations," said Dr. Sindhi, an associate professor of surgery at the University of Pittsburgh School of Medicine. "By applying individualized anti-rejection strategies before the transplant even occurs, we hope to reduce rejection rates and drug-induced side effects for pediatric liver transplant from 50 percent to about 20 percent."

Surgical techniques have improved survival rates for pediatric organ transplantation dramatically over the last 25 years. As a result, the challenge has shifted to improving quality of life. Anti-rejection medications are important because, while they make transplantation possible, they also can have adverse side effects that can themselves become life-threatening, such as infections and cancers.

Researchers will study the multiple processes that cause rejection in blood cells. This information will be linked to the unique "genomic fingerprint" of a liver transplant candidate, based on the inheritance of more than 500,000 mutations from parent to child. These mutati
'"/>

Contact: Marc Lukasiak
marc.lukasiak@chp.edu
412-692-7919
Children's Hospital of Pittsburgh
11-Oct-2006


Page: 1 2

Related biology news :

1. Study begins to reveal clues to the cause and progression of sepsis
2. Study finds gender differences in renal and other genes contributing to blood pressure
3. Study suggests estrogen deficiency can lead to obesity-induced high blood pressure after menopause
4. Study: Sticking to the sand might not be such good, clean fun for beachgoers
5. Study points to new way to predict death risk from torn aorta
6. Study identifies new gene therapy tools for inherited blindness
7. Study finds contaminated water reaching Floridas offshore keys
8. Study sheds light on why humans walk on two legs
9. Study explains how pathogens evolve to escape detection
10. Study finds hereditary link to premenstrual depression
11. Study identifies energy efficiency as reason for evolution of upright walking

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/25/2020)... Mass. (PRWEB) , ... June 24, 2020 , ... ... of cloud-based enterprise software and software-driven clinical data services that accelerate drug development, ... for low-dose selinexor, an XPO1 inhibitor, in hospitalized patients with severe COVID-19. This ...
(Date:6/23/2020)... KEYNES, England (PRWEB) , ... June 23, 2020 ... ... in Africa supporting sustainable healthcare, and Renovagen Ltd, a UK supplier and manufacturer ... response project to support testing operations in the fight against the COVID-19 pandemic ...
(Date:6/23/2020)... Texas (PRWEB) , ... June 23, 2020 , ... ... analytical instrumentation, is pleased to announce the next event in a series of ... scattering. , The TOPIQ series of webinars was developed in response to social ...
Breaking Biology News(10 mins):
(Date:8/31/2020)... , ... August 29, 2020 , ... ... Animal Nutrition manufacturing capability in Wuxi, China. The new plant operation will provide ... standards and advanced technology. , “This facility will improve the flexibility of ...
(Date:8/12/2020)... ... August 11, 2020 , ... ... expand the Facioscapulohumeral Muscular Dystrophy Clinical Trial Research Network (FSHD CTRN), ... The network is a consortium of academic research centers in the United States ...
(Date:8/7/2020)... ... August 06, 2020 , ... VGXI, a highly ... closed on the purchase of greenfield for a new, expanded manufacturing facility. The ... 21 acres in the initial acquisition, with an option to purchase an additional ...
(Date:7/31/2020)... ... July 29, 2020 , ... R3 Stem Cell International is ... $3950. With 50 million stem cells total, patients may choose which extremities they would ... for arthritic joints (BMC Musculoskelet Disord. 2016). At R3 International, umbilical cord tissue is ...
Breaking Biology Technology:
Cached News: